Quantcast

Latest Neurotech Pharmaceuticals Inc. Stories

2009-05-28 07:32:00

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which...

2008-10-21 09:00:54

CUMBERLAND, R.I., Oct. 21 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today the opening of its new 27,000 square-foot GMP manufacturing facility in Cumberland, Rhode Island. With support from the Rhode Island Economic Development Corporation (RIEDC) and its financing programs, Rhode Island Industrial Facilities Corporation (RIIFC) and Rhode Island...

2008-09-03 09:00:46

LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for NT-501 for the treatment of visual loss in two indications -- retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related